Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.

Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.

<h4>Objective</h4>Investigators have extensively explored the short-term safety and efficacy data on 177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients. However, scarce literature is reported on the long-term outcome of these patients. The current goal of this study is focused on...

Full description

Bibliographic Details
Main Authors: Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Madhavi Tripathi, Nishikant Avinash Damle, Shamim Ahmed Shamim, Rakesh Kumar, Amlesh Seth, Chandrasekhar Bal
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0251375

Internet

https://doi.org/10.1371/journal.pone.0251375

Similar Items